Evidence map›Paper›PMID 40990085›Full record

ArticleMovement disorders clinical practice2026

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease.

Andrea Sturchio, Wojciech Paslawski, Shervin Khosousi, Ioanna Markaki, Michael A Nalls, Andrew B Singleton, Hirotaka Iwaki, Per Svenningsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrea SturchioDepartment of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.
Wojciech PaslawskiDepartment of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-2141-4547
Shervin KhosousiDepartment of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.
Ioanna MarkakiDepartment of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-3328-5746
Michael A NallsCenter for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Andrew B SingletonCenter for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Hirotaka IwakiCenter for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Per SvenningssonDepartment of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-6727-3802

Funding

Knut och Alice Wallenbergs StiftelseMichael J. Fox Foundation for Parkinson's ResearchNIH HHSRegion Stockholm
6 · The paper itself

Abstract

backgroundDOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear.

objectivesWe aimed to determine if baseline DDC was associated with future cognitive decline in PD.

methodsWe correlated baseline CSF DDC, detected using the proximity extension assay, with Montreal Cognitive Assessment (MoCA) score using longitudinal data from 3 cohorts: Biopark, PPMI, and PDBP.

resultsDDC was significantly associated with cognitive decline in both the Biopark cohort (P-value < 0.0001) and the PDBP/PPMI cohorts (P-value < 0.0001). The results were still significant after correcting for levodopa-equivalent daily dose in the Biopark cohort (P-value < 0.0001) and when the analysis was restricted to the de novo subjects, both in Biopark (P-value: 0.0065) and PPMI (P-value<0.0001) cohorts.

conclusionsCSF DDC is a potential biomarker for the prediction of cognitive decline in PD patients.

Indexed as

Cognitive DysfunctionDopa DecarboxylaseParkinson DiseaseAgedBiomarkersCohort StudiesFemaleHumansLongitudinal StudiesMaleMental Status and Dementia TestsMiddle AgedNeuropsychological TestsBiomarkersDopa Decarboxylasebiomarkerscognitive impairmentDOPA decarboxylase (DDC)nonmotor symptomsParkinson's disease

Identifiers

PMID40990085
PMCPMC13042671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.